⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Amicus Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Amicus Therapeutics
↗Princeton, New Jersey, USA
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. The company is known for its work in pharmacological chaperones and enzyme replacement therapies, with a strong emphasis on lysosomal storage disorders such as Fabry and Pompe disease.
As of April 2026, Amicus Therapeutics operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc. following a $4.92 billion acquisition. The company maintains a global footprint with its headquarters in Princeton, New Jersey, and international operations across more than 20 countries, continuing its mission to advance first- or best-in-class therapies for rare disease communities.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:2002
Ownership:subsidiary
Status:acquired
FUNDING
Investors:Radius Ventures, Canaan Partners, New Enterprise Associates
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Enzyme replacement therapy, Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:BioMarin Pharmaceutical Inc.
Acquired By:BioMarin Pharmaceutical Inc. (2026-04-01)
Key Partnerships:BioMarin Pharmaceutical (Parent)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Bradley L. Campbell - CEO
John F. Crowley - Chairman Emeritus
LINKS
Website:amicusrx.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Amicus Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.